At present, NovoCure currently has a gross margin of 77%, an operating margin of -17.2%, an EBITDA margin of -14.8%, and a net margin of -16.8%; its operating margin is negative at -17.2%, its EBITDA margin is negative at -14.8%, and its net margin is negative at -16.8%. Each available margin advanced from the same period last year. Net margin recorded the strongest gain, gaining by 10.9 percentage points.
NovoCure's margins averaged 75.91% gross, -28.95% operating, -26.84% EBITDA, and -27.29% net during the last 3 years. Currently all four current margins are above their three-year averages.
All available margins expanded year over year, led by net margin with an increase of 10.9 percentage points.
Over the last 3 years, NovoCure's gross margin averaged 75.91%. Currently, NovoCure's current gross margin is 77%, which is 1.1 percentage points above its three-year average. During this period, gross margin reached a high of 77.3% in Dec 2024 and a low of 74.5% in Dec 2025.
NovoCure recorded an average operating margin of -28.95% across the last 3 years. Currently, the current operating margin for NovoCure is -17.2%, 11.8 percentage points above its three-year average. Looking back over the last 3 years, NovoCure's operating margin reached -17.2% at its highest point in Sep 2026 and -45.7% at its lowest in Dec 2023.
Across the last 3 years, NovoCure's EBITDA margin averaged -26.84%. The current EBITDA margin stands at -14.8%, 12 percentage points above its three-year average. EBITDA margin was highest at -14.8% in Sep 2026 and lowest at -43.6% in Dec 2023.
Over the last 3 years, NovoCure had an average net margin of -27.29%. The current net margin of -16.8% is 10.5 percentage points above its three-year average. Looking back over the last 3 years, NovoCure's net margin reached -16.8% at its highest point in Sep 2026 and -40.6% at its lowest in Dec 2023.
With a gross margin of 77%, NVCR ranks higher than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 68.6%, NovoCure's gross margin is 12% higher.
For the period ending Sep 30, 2026, NVCR recorded a gross margin of 77%.
The current operating margin for NVCR is -17.2% as of Sep 30, 2026.
As of Sep 30, 2026, NVCR has an EBITDA margin of -14.8%.
As of Sep 30, 2026, NVCR has a net margin of -16.8%.
Over the last 3 years, NovoCure's margins averaged 75.9% gross, -29.0% operating, -26.8% EBITDA, and -27.3% net.
Within the 5-year period, NVCR recorded its highest margins at 78.7% gross in Sep 2022, -8.3% operating in Dec 2021, -6.4% EBITDA in Mar 2022, and -10.9% net in Mar 2022.
Looking back across 5 years, NVCR reached its lowest margins at 74.5% gross in Dec 2025, -45.7% operating in Dec 2023, -43.6% EBITDA in Dec 2023, and -40.6% net in Dec 2023.